Colorectal Cancer

Sequence of therapies may be more significant versus single agents in treating patients with metastatic colorectal cancer.

Charles S. Fuchs, MD, discusses a recent study which found that consuming four or more cups of coffee per day may reduce risk of recurrence by 42% and death by 34% in patients with stage III colon cancer.

Recent evidence has shed some light on the prognostic value of microsatellite instability and the potential benefit of checkpoint inhibition in colorectal cancer.

Rocio Garcia-Carbonero, MD, PhD, Universidad de Sevilla, discusses the quality of life results from the RAISE study. The RAISE study was a phase III randomized, double-blind study of FOLFIRI plus ramucirumab or placebo in patients with metastatic colorectal cancer (mCRC) after first-line therapy with bevacizumab, oxaliplatin, or fluoropyrimidine.

Nadir Arber, MD, MHA, Yechiel and Helen Lieber Chair for Cancer Research at Tel Aviv Sourasky Medical Center and Tel Aviv University, Sackler School of Medicine, Professor of Medicine and Gastroenterology and Director of the Integrated Cancer Prevention Center (ICPC) in Tel-Aviv Medical Center, discusses the role of aspirin in the prevention of colorectal cancer.

Luis A. Diaz, Jr. MD, associate professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, discusses the efficacy of PD-1 inhibitor pembrolizumab (Keytruda) in heavily pretreated colorectal cancer patients with mismatch repair (MMR).

Axel Grothey, MD, department of Oncology, Mayo Clinic, Rochester, MN, discusses the differences between the CORRECT and CONCUR trials, which both looked at regorafenib for previously treated metastatic colorectal cancer (mCRC).

Eric Van Cutsem, MD, PhD, discusses results from the phase IIIb CONSIGN study and the continuing advance of precision medicine in colorectal cancer.